Ginkgo Bioworks Holdings Inc vs iShares Bitcoin Trust — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while iShares Bitcoin Trust trades at $37.06. The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| DNA | IBIT | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Crypto-linked |
52-Week High | $16.14 | $71.29 |
52-Week Low | $5.48 | $33.29 |
Enterprise Value | $627.78M | — |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
IBIT trades at $35.22, down 2.79% today, reflecting recent bearish pressure. Technical indicators show a predominantly bearish trend with moving averages signaling sell conditions, while oscillators remain neutral. The stock faces resistance at $36 and finds support at $35. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing competitors like Fidelity's offering as of June 29, 2026 (The Motley Fool).
The outlook for IBIT hinges on Bitcoin ETF flows and market sentiment toward crypto assets. Investment opportunities include its dominant market share and low expense ratio, but risks involve significant outflows from Bitcoin ETFs, with a record $4.5 billion in June 2026 (Zacks Investment Research, July 6, 2026), and volatility linked to cryptocurrency price swings.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →